ERCIYES MEDICAL JOURNAL, cilt.40, sa.1, ss.28-34, 2018 (ESCI)
Objective: This study aimed to determine the frequency of HBV reactivation and the potential predictive factors in resolved hepatitis B virus (HBV) patients [hepatitis B surface antigen (HBsAg)-negative and antibody to hepatitis B core antigen (antiHBc)-positive patients] who received rituximab-containing chemotherapy for B-cell lymphoma.